Skip to content

Trial · Interventional

Status unknownPhase 4Registry data

Methods Decreasing Bleeding in Open Myomectomy

Overview

Status
Status unknown
Phase
Phase 4
Enrollment
105 participants (estimated)
Sponsor
Cairo University · Other
Design
Randomized · Double masking
Countries
1 country

Egypt

Start
15 Mar 2023
Primary completion
30 Oct 2023 (estimated)
Completion
30 Nov 2023 (estimated)
First posted
10 Apr 2023
Last update posted
10 Apr 2023
Conditions
Misoprostol Allergy · Oxytocin Allergy · Tranexamic Acid Allergy · Ethamsylate Allergy · Myoma · Blood Loss, Surgical

Timeline

1 trial

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20232024
  1. Ph 4

    Methods Decreasing Bleeding in Open Myomectomy

    NCT05806307

    15 Mar 2023 to est. 30 Nov 2023

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Uterine leiomyomas (fibroids or myomas) are benign, smooth muscle tumors of the human uterus. Most myomas are asymptomatic (symptomless) and are discovered incidentally during a routine pelvic examination or imaging studies and have a lifetime incidence of approximately 70% in the general population . However, Approximately 20-40% of women with fibroids experience significant symptoms and consult gynecologic care. The most common clinical symptoms include abnormal uterine bleeding, dysmenorrhea, pelvic pain, infertility, and recurrent pregnancy loss The standard treatment of symptomatic leiomyomas is Abdominal myomectomy Blood loss during myomectomy can be intra-operative or postoperative and with hematoma formation. The average volume of blood loss during abdominal myomectomy is 200 to 800 ml. massive blood loss associated with the dissection of huge fibroids renders myomectomy a more technically challenging procedure than hysterectomy. Sometimes myomectomy is converted to hysterectomy intra-operatively when bleeding becomes heavy and uncontrollable or when it is impossible to reconstruct the uterus because of the many defects left by removal of multiple myomas . Many techniques are used to reduce blood loss during myomectomy; preoperative measures such as correction of preoperative anemia associated with menorrhagia may be treated with iron supplementation, use of gonadotropin (GHG) triggers prior to surgery. Intra-operative measures as use of tourniquet around the uterus during the operation, injections of Vasopressin or other vasopressors as epinephrine in the uterine muscle and use of ecbolic (misoprostol, oxytocin, and carbetocin etc.). Uterine artery ligation, embolization, or internal iliac artery ligation may also be used to avoid hysterectomy when heavy bleeding is anticipated or occurs during myomectomy

Interventions

  • MisoprostolDrug
  • TourniquetDevice
  • CarbetocinDrug
  • OxytocinDrug
  • combined TXA and ethamsylateDrug
  • VasopressinDrug
  • Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrineDrug

Arms7

  • Active comparator

    misoprostol

    15 patients will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.

  • Active comparator

    Tourniquet

    (15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine

  • Active comparator

    Carbetocin

    intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.

  • Active comparator

    Oxytocin

    15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.

  • Active comparator

    combined TXA and ethamsylate

    (Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.

  • Active comparator

    vasopressin

    15 women will receive terlipressin (Glypressin, Ferring, Egypt) intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.

  • Active comparator

    bupivacaine and epinephrine

    15 women in which the operation will be performed after infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. blood loss

    Time frame · 3 hours

    Registry description

    the estimated intra-operative blood loss in ml

Secondary outcomes(5)
  1. blood transfusion

    Time frame · 24 hours

    Registry description

    Number of patients in each group who require transfusion and how many units they need

  2. Preoperative and postoperative hemoglobin values

    Time frame · 48 hours

    Registry description

    will be measured in g/dl on 24 hours before and 24 hours after surgery

  3. Perioperative blood pressure

    Time frame · 4-6 hours

    Registry description

    Measure blood presure in mmhg at start and end of operation and then every hour interval up to first four hours postoperative

  4. the duration of hospital stays

    Time frame · 3 day

    Registry description

    How many days patient stay in hospital after surgery for recovery

  5. Operation time

    Time frame · 3 hours

    Registry description

    measured from incision of first myoma to serosal closure of last myoma wound in minutes

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Meta-analysis (pooled) · 2014

2 results

Interventions to reduce haemorrhage during myomectomy for fibroids.

Kongnyuy et al. 2014The Cochrane database of systematic reviewscited by 38

PMID 25125317PMC9017065DOI 10.1002/14651858.cd005355.pub5PUB-25125317

Rights unknown2 results

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • ResultCamanni M, Bonino L, Delpiano EM, Ferrero B, Migliaretti G, Deltetto F. Hysteroscopic management of large symptomatic submucous uterine myomas. J Minim Invasive Gynecol. 2010 Jan-Feb;17(1):59-65. doi: 10.1016/j.jmig.2009.10.013. PMID 20129334

Eligibility

Who could join, as posted.

Sex
Female
Age
from 25 Years up to 48 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: 1. patients aged between 25 to 48 years old. 2. BMI less than 35 kg/m2 3. symptomatic uterine myomas.. 4. myoma staging from (3 to 6) according to FIGO staging through trans vaginal ultrasonography (TVUSG) or magnetic resonance imaging (MRI) according to FIGO classification. 5. Maximum diameter of the largest myoma is 15 cm. 6. Uterine size between 14 to 28 weeks pregnancy. Exclusion Criteria: 1. History of previous myomectomy 2. Allergy to Misoprostol, carbetocin, TXA, ethamsylate, Oxytocin, vasopressin, bupivacaine and epinephrine. 3. Hypertension. 4. Cardiac and Pulmonary diseases. 5. Patients who have bleeding disorders. 6. Patients on antiplatelets or anticoagulant before surgery. 7. Anemia (Hb \< 10g %). 8. Chronic endocrine or metabolic diseases such as Diabetes. 9. Renal and hepatic impairment. 10. Obesity (body mass index \> 30 kg/m2). 11. Cases that will require intraoperative conversion of myomectomy to hysterectomy. 12. Intracavitary, submucosal, pedunculated Subserosal and adnexal Myoma FIGO staging 0,1,2,7,8. 13. history of Gynecological infections (PID), history of abdominal infections e.g.: peritonitis, history of any abdominal or pelvic operation for non-obstetric cause.

PepBank is a research reference. Talk to a doctor before you use any peptide.